IRIS PubliCatt

Borghetti, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.218
EU - Europa 2.076
AS - Asia 547
AF - Africa 52
OC - Oceania 25
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 4.930
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.187
IT - Italia 482
SE - Svezia 480
DE - Germania 249
PL - Polonia 217
FR - Francia 198
CN - Cina 191
IE - Irlanda 135
SG - Singapore 123
GB - Regno Unito 97
IN - India 69
UA - Ucraina 56
FI - Finlandia 48
RU - Federazione Russa 37
CA - Canada 27
IR - Iran 27
AU - Australia 24
TR - Turchia 20
SA - Arabia Saudita 19
BE - Belgio 16
CI - Costa d'Avorio 15
PH - Filippine 15
HK - Hong Kong 14
NL - Olanda 11
PK - Pakistan 11
MY - Malesia 10
CH - Svizzera 9
EG - Egitto 9
VN - Vietnam 8
TW - Taiwan 7
AT - Austria 6
TN - Tunisia 6
BD - Bangladesh 5
CZ - Repubblica Ceca 5
ES - Italia 5
NG - Nigeria 5
EU - Europa 4
GR - Grecia 4
IL - Israele 4
MA - Marocco 4
RO - Romania 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
JO - Giordania 3
MD - Moldavia 3
NP - Nepal 3
PT - Portogallo 3
SD - Sudan 3
TH - Thailandia 3
BG - Bulgaria 2
BR - Brasile 2
CL - Cile 2
CM - Camerun 2
CO - Colombia 2
JP - Giappone 2
KE - Kenya 2
LT - Lituania 2
MG - Madagascar 2
MM - Myanmar 2
MO - Macao, regione amministrativa speciale della Cina 2
NO - Norvegia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CY - Cipro 1
GL - Groenlandia 1
IM - Isola di Man 1
IQ - Iraq 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MX - Messico 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
TT - Trinidad e Tobago 1
Totale 4.930
Salva come PNG Salva come JPEG
Città #
Chandler 616
Ashburn 229
Kraków 209
Dublin 132
New York 127
Rome 111
Milan 86
San Mateo 79
Singapore 75
Jacksonville 60
Boston 58
Ann Arbor 47
Princeton 47
Wilmington 47
Marseille 40
Redmond 33
Nanjing 32
Los Angeles 29
Moscow 29
Chicago 28
Beijing 27
Helsinki 27
Lancaster 27
Cattolica 26
Boardman 22
Dearborn 20
Houston 20
Pune 18
Fairfield 17
Lawrence 17
London 17
Abidjan 15
Woodbridge 15
Augusta 14
Bremen 13
Brussels 13
Redwood City 13
Seattle 13
Norwalk 12
Dammam 11
Izmir 11
Kish 11
Nürnberg 11
Washington 11
Andover 9
Cambridge 8
Changsha 8
Hong Kong 8
Sydney 8
Al Qatif 7
Leawood 7
Warsaw 7
Amsterdam 6
Oggiono 6
Shenyang 6
Toronto 6
Cairo 5
Ferrara 5
Guangzhou 5
Lahore 5
Nanchang 5
Naples 5
St Louis 5
Swansea 5
Taipei 5
Tianjin 5
Vienna 5
Zurich 5
Bari 4
Boydton 4
Cape Town 4
Castelfranco Emilia 4
Delhi 4
Falls Church 4
Hebei 4
Hefei 4
Munich 4
Paris 4
Phoenix 4
Robbiate 4
Sacramento 4
Springfield 4
Thrissur 4
Amman 3
Bacolod City 3
Bournemouth 3
Brno 3
Busto Arsizio 3
Central 3
Clearwater 3
Dhaka 3
Fuzhou 3
Gunzenhausen 3
Hamburg 3
Hanover 3
Ho Chi Minh City 3
Irvine 3
Jinan 3
Karachi 3
Khartoum 3
Totale 2.772
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 423
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 166
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 161
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 155
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 134
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 132
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 129
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 127
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 119
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 118
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 115
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 102
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 99
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 92
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 89
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 86
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 86
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 77
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 76
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 74
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 71
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 71
Shall we dance? Extending tango's results to clinical practice 68
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 67
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 67
Residual respiratory impairment after COVID-19 pneumonia 64
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 61
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 60
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 59
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 59
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 59
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 56
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 55
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 55
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 54
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 53
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 52
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 52
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 51
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 51
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 51
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 50
SARS-CoV-2 infection in a highly experienced person living with HIV 49
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients 49
People Living with HIV in the COVID-19 Era: A Case Report 47
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 46
Focal status epilepticus as unique clinical feature of COVID-19: A case report 46
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 45
Residual respiratory impairment after COVID-19 pneumonia 44
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 43
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 42
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 41
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV 39
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 38
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 36
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 36
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 35
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 35
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 33
People Living with HIV in the COVID-19 Era: A Case Report 32
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 31
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 31
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 30
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 30
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 30
Real-life findings on the impact of the COVID-19 pandemic on HIV care 29
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 27
COVID-19 diagnosis does not rule out other concomitant diseases 27
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 26
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine-Dolutegravir 26
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 23
Kaposi-like manifestations in a newly diagnosed aids transgendered patient with silicone embolism syndrome and disseminated tuberculosis 20
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 17
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 15
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study 13
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 11
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 11
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 11
Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy 11
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 8
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 7
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 6
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 6
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 6
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 6
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 5
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 4
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 4
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 2
Totale 5.055
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.968
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.968
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020191 0 10 14 7 24 25 16 14 13 16 34 18
2020/2021234 4 15 4 13 16 21 21 10 39 36 44 11
2021/2022695 33 21 16 73 19 22 65 116 31 52 85 162
2022/20232.016 207 253 176 322 209 269 82 154 217 54 54 19
2023/20241.103 43 223 36 98 59 179 76 30 39 51 135 134
2024/202548 27 21 0 0 0 0 0 0 0 0 0 0
Totale 5.055